menu
    • menu
    [{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Hugel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Croma-Pharma \/ Hugel","highestDevelopmentStatusID":"8","companyTruncated":"Croma-Pharma \/ Hugel"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ China National Biotech Group","highestDevelopmentStatusID":"15","companyTruncated":"Croma-Pharma \/ China National Biotech Group"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Saypha Volume Lidocaine","moa":"Homeostasis","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Saypha Volume Lidocaine","moa":"Homeostasis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Croma-Pharma \/ Croma-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Croma-Pharma \/ Croma-Pharma"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Termination","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Croma-Pharma \/ Croma-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Croma-Pharma \/ Croma-Pharma"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Gerhard Garhofer","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Chitosan Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Croma-Pharma \/ Gerhard Garhofer","highestDevelopmentStatusID":"8","companyTruncated":"Croma-Pharma \/ Gerhard Garhofer"}]

    Find Clinical Drug Pipeline Developments & Deals by Croma-Pharma

    Menu

    Croma-Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Crescita Therapeutics

                            Deal Size : $0.5 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Crescita Announces Mutual Termination of Licensing Agreement with Croma for Pliaglis

                            Details : Under the mutual agreement, Crescita has terminated its commercialization and development license agreement with CROMA that granted Croma exclusive rights to market Pliaglis in Germany, UK etc.

                            Product Name : Pliaglis

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 23, 2025

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Crescita Therapeutics

                            Deal Size : $0.5 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Lidocaine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Croma-Pharma Announces Enrollment of First Patient in Hyaluronic Acid Dermal Filler Clinical Trial in China

                            Details : Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.

                            Product Name : Princess Volume Plus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 12, 2023

                            Lead Product(s) : Hyaluronic Acid,Lidocaine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saypha Volume Lidocaine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saypha® VOLUME Lidocaine for Midface Augmentation

                            Details : Saypha Volume Lidocaine is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Midface volume deficiency.

                            Product Name : Undisclosed

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 23, 2022

                            Lead Product(s) : Saypha Volume Lidocaine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Crescita Therapeutics

                            Deal Size : $1.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®

                            Details : Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other mi...

                            Product Name : Pliaglis

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 28, 2021

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Crescita Therapeutics

                            Deal Size : $1.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmen...

                            Details : Lidocaine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lip Abnormalities.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2021

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saypha Volume Lidocaine

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saypha® Volume LIdocaine in Nasolabial Folds

                            Details : Saypha Volume Lidocaine is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in clinical studies for the treatment of Nasolabial Fold.

                            Product Name : Undisclosed

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 12, 2021

                            Lead Product(s) : Saypha Volume Lidocaine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Hugel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Frown Lines.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Hugel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : China National Biotech Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Croma Establishes New Joint Venture in China

                            Details : The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin produc...

                            Product Name : Princess Volume Plus

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 15, 2020

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : China National Biotech Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum Toxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Croma-Pharma Announces Submission for Their Botulinum Toxin to Treat Glabellar (frown) Lines to the German Aut...

                            Details : Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.

                            Product Name : BoNT/A-DP

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 08, 2020

                            Lead Product(s) : Botulinum Toxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glabellar Frown Lines.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 14, 2019

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth